European Commission approves AbbVie’s Skyrizi (Risankizumab) to Treat Adults with Active Psoriatic Arthritis.
KEYPOINTS: AbbVie announces that the European Commission (EC) has approved SKYRIZI (Risankizumab, 150 mg, subcutaneous injection at week 0, week 4, and…